发明授权
US5840710A Cationic amphiphiles containing ester or ether-linked lipophilic groups
for intracellular delivery of therapeutic molecules
失效
含有酯或醚连接的亲脂基团的阳离子两亲物用于治疗分子的细胞内递送
- 专利标题: Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
- 专利标题(中): 含有酯或醚连接的亲脂基团的阳离子两亲物用于治疗分子的细胞内递送
-
申请号: US546087申请日: 1995-10-20
-
公开(公告)号: US5840710A公开(公告)日: 1998-11-24
- 发明人: Edward R. Lee , David J. Harris , Craig S. Siegel , Mathieu B. Lane , Shirley C. Hubbard , Seng H. Cheng , Simon J. Eastman , John Marshall , Ronald K. Scheule
- 申请人: Edward R. Lee , David J. Harris , Craig S. Siegel , Mathieu B. Lane , Shirley C. Hubbard , Seng H. Cheng , Simon J. Eastman , John Marshall , Ronald K. Scheule
- 申请人地址: MA Framingham
- 专利权人: Genzyme Corporation
- 当前专利权人: Genzyme Corporation
- 当前专利权人地址: MA Framingham
- 主分类号: A61K9/127
- IPC分类号: A61K9/127 ; A61K47/48 ; A61K48/00 ; C07J41/00 ; C07J43/00 ; C12N15/88 ; A61K38/00 ; C07C53/00 ; C07C69/74
摘要:
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.
信息查询